BUFFALO, N.Y., Jan. 14, 2016 /PRNewswire/ -- Albany
Molecular Research Inc. (NASDAQ: AMRI) announced today that it has
signed a collaboration agreement with the New York Center for
Nanomedicine Research (NYCNMR) to co-market their nanotechnology
services to global pharmaceutical and biotechnology clients.
As part of the three-year agreement, AMRI gains access to
NYCNMR's nanoscale therapeutic and formulation services. NYCNMR's
customers will benefit from AMRI's suite of integrated drug
discovery solutions, which includes expertise in assay method
development, high-throughput screening, high-content screening,
hit-to-lead-medicinal chemistry, computer-aided drug discovery and
in vitro DMPK assays, as well as access to its proprietary
ASCC small molecule and natural products collections
"We are very enthusiastic about our collaboration with NYCNMR as
it represents a unique opportunity to provide drug discovery
customers with cutting-edge nanotechnologies and an environment
that can create preventative, diagnostic and therapeutic approaches
to treat a variety of human diseases," said Rory Curtis, Ph.D., Vice President, Discovery
Biology and Pharmacology, and Site Head of AMRI Buffalo. "NYCNMR's
expertise – specifically in the area of drug delivery and targeting
systems – has the ability to enrich the industry's drug discovery
efforts across biology, chemistry and pharmacology by applying
cutting-edge nanotechnologies to clinical applications in order to
solve complex medical problems."
Housed at the University at
Buffalo's Clinical and Translational Research Center on the
Buffalo Niagara Medical Campus, NYCNMR is working with
pharmaceutical companies, academic researchers and corporate
clients on commercialization efforts by applying nanotechnology to
clinical applications.
"We are excited to bring our nanotechnology capabilities and
services to AMRI's customers through this strategic collaboration,"
added Scottpatrick J. Sellitto, Founding Partner and CEO, NYCNMR.
"We believe there is much for our customers and the industry to
gain from accessing the integrated capabilities that AMRI's new
center in Buffalo offers for drug
discovery."
"The agreement between AMRI and NYCNMR represents the continued
realization of Governor Andrew
Cuomo's vision for the Buffalo Medical Innovation and
Commercialization Hub (BMIC) to build upon Western New York's leadership in life sciences
research and enable the commercialization of innovations developed
there," said Tom O'Brien, Associate
Vice President for Innovation Infrastructure and Resources for SUNY
Polytechnic Institute, which manages the BMIC. "We applaud AMRI and
NYCNMR on their new partnership and look forward to further
industry collaborations and growth at the Buffalo hub."
About AMRI
Albany Molecular Research Inc. (AMRI) is a
global contract research and manufacturing organization that has
been working with the Life Sciences industry to improve patient
outcomes and the quality of life for more than two decades. With
locations in North America,
Europe and Asia, our key business segments include
Discovery and Development Solutions (DDS), Active Pharmaceutical
Ingredients (API), and Drug Product Manufacturing (DPM). Our DDS
segment provides comprehensive services from hit identification to
IND, including expertise with diverse chemistry, library design and
synthesis, in vitro biology and pharmacology, drug metabolism and
pharmacokinetics, as well as natural products. API supports the
chemical development and cGMP manufacture of complex API, including
potent, controlled substances, biologics, peptides, steroids,
hormones, cytotoxic compounds and sterile API. DPM supports
development through commercial scale production of complex
liquid-filled and lyophilized parenterals, sterile suspensions and
ophthalmic formulations. For more information about AMRI, please
visit our website at www.amriglobal.com or follow us on Twitter
(@amriglobal).
About NYCNMR
The New York Center for Nanomedicine
Research Inc. (NYCNMR) promotes and achieves efficient integration
of cutting edge nanotechnology and medical research. The center has
expertise in medicine, advanced nanoparticle development, targeted
delivery systems for drugs and biologics, and has developed novel
transfection and transport platforms. The primary goal of the
Center is the translation of nanotechnology into clinical
applications leading to commercialization opportunities. The center
provides an interdisciplinary scientific environment to create new
approaches to prevent, diagnose and treat immunological,
infectious, cardiovascular, neurological, and oncological diseases.
NYCNMR is housed on the Buffalo Niagara Medical Campus ("BNMC") at
the University of Buffalo's
Clinical and Translational Research Center. For more information on
the NYCNMR please visit www.nycnmr.com.
SUNY Polytechnic Institute
SUNY Polytechnic Institute
(SUNY Poly) is New York's globally
recognized, high-tech educational ecosystem, formed from the merger
of the SUNY College of Nanoscale Science and Engineering and
SUNY Institute of Technology. SUNY Poly
offers undergraduate and graduate degrees in the emerging
disciplines of nanoscience and nanoengineering, as well as
cutting-edge nanobioscience and nanoeconomics programs at its
Albany location and undergraduate
and graduate degrees in technology, including engineering,
cybersecurity, computer science, and the engineering technologies;
professional studies, including business, communication, and
nursing; and arts and sciences, including natural sciences,
mathematics, humanities, and social sciences at its Utica/Rome
location. Thriving athletic, recreational, and cultural programs,
events, and activities complement the campus experience. As the
world's most advanced, university-driven research enterprise, SUNY
Poly boasts more than $43 billion in
high-tech investments, over 300 corporate partners, and maintains a
statewide footprint. The 1.3 million-square-foot Albany NanoTech
megaplex is home to more than 4,000 scientists, researchers,
engineers, students, faculty, and staff, in addition to Tech Valley
High School. SUNY Poly operates the
Smart Cities Technology Innovation Center (SCiTI) at Kiernan Plaza
in Albany, the Solar Energy
Development Center in Halfmoon,
the Central New York Hub for Emerging Nano Industries in
Syracuse, the Smart System
Technology and Commercialization Center (STC) in Canandaigua, and the Photovoltaic
Manufacturing and Technology Development Facility in Rochester where SUNY Poly also leads the
American Institute for Manufacturing Integrated Photonics. SUNY
Poly founded and manages the Computer Chip Commercialization Center
(Quad-C) at its Utica location and
also manages the $500 million New
York Power Electronics Manufacturing Consortium, with nodes in
Albany and Rochester, as well as the Buffalo High-Tech
Manufacturing Innovation Hub at RiverBend, Buffalo Information
Technologies Innovation and Commercialization Hub, and Buffalo
Medical Innovation and Commercialization Hub. For information visit
www.sunycnse.com and www.sunypoly.edu.
About Nanotechnology
Nanotechnology is science,
engineering, and technology involving matter on an atomic,
molecular, and supramolecular scale. According to BCC Research, the
global market for nanotechnology products was valued at
$26 billion in 2014. It is estimated
to reach about $64.2 billion by 2019,
a compound annual growth rate (CAGR) of 19.8% from 2014 to
2019.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/amri-and-nycnmr-form-collaborative-agreement-300203444.html
SOURCE AMRI